Anti-CCP antibodies have a high specificity for the diagnosis of rheumatoid arthritis. Anti-CCP antibody, i.e. anti-cyclic citrullinated peptide antibody, is mainly used in the diagnosis of rheumatoid arthritis, and has high specificity and sensitivity in the diagnosis of rheumatoid arthritis. Currently, anti-CCP antibody has been listed as one of the criteria for the classification and diagnosis of rheumatoid arthritis, and there is clear clinical evidence to prove that bone destruction is more serious in anti-CCP antibody-positive rheumatoid arthritis patients than anti-CCP antibody-negative patients. In addition, anti-CCP antibody-positive rheumatoid arthritis patients experience irreversible bone damage faster than anti-CCP antibody-negative patients. However, anti-CCP antibody-positive patients cannot directly diagnose rheumatoid arthritis based on anti-CCP antibody alone, and should be analyzed in conjunction with the patient’s symptoms, medical history, physical signs, and other ancillary tests. Anti-CCP antibody test results should be interpreted by a professional physician, and it is recommended that patients go to the Department of Rheumatology and Immunology of a regular hospital for detailed consultation.